Prognostic value of cardiopulmonary biomarkers in relation to the development of bronchopulmonary dysplasia and pulmonary hypertension in premature infants

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033219

Enrollment

100

Registered

2023-12-13

Start date

2021-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

P27.1 P29.3 P29.0

Interventions

Group 1: Preterm infants born =30 weeks of gestational age (GA) with a birth weight of <1500g (very low birht weight/ VLBW) Test plan In addition to the blood samples taken as part of the regular tre

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Birth weight <1500g

Exclusion criteria

Exclusion criteria: =30/1 weeks of GA, early death (<7 days of life), primary palliative care, congenital heart defects (CHD) requiring surgical repair. A patent ductus arteriosus (PDA), an atrial septal defect (ASD, <5mm) and a muscular ventricular septal defect (VSD, <2mm) were not classified as relevant CHD.

Design outcomes

Primary

Measure	Time frame
Combined primary endpoint: diagnosis of bronchopulmonary dysplasia (BPD) and/or death (whichever occurs first)	—

Secondary

Measure	Time frame
1) The development of pulmonary hypertension 2) The development of right ventricular or left ventricular cardiac dysfunction 3) Duration of supplemental oxygen administration 4) Duration of mechanical ventilation 5) Duration of hospital stay	—

Countries

Germany

Contacts

Public ContactLukas Schröder

Universitätsklinikum Bonn

lukas.schroeder@ukbonn.de+4922828737821

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026